ACOG Practice Bulletin No. 190: Gestational Diabetes Mellitus

Maternal and neonatal outcomes with different screening strategies for gestational diabetes mellitus: a retrospective cohort study

OBJECTIVE

To evaluate the effect of an expanded gestational diabetes mellitus (GDM) screening strategy on perinatal outcomes.

METHODS

This retrospective cohort study included gravidas screened for GDM at a single academic center. The "before" cohort (estimated due dates (EDD) March 2018-April 2019) was screened using the standard 2-step method. The "after" cohort (EDD November 2019-July 2023) was screened using an expanded strategy that included the potential for GDM diagnosis based on 1-2 weeks of home glucose monitoring following isolated fasting hyperglycemia on the 3-hour glucose tolerance test (GTT). The primary outcomes were primary cesarean delivery (PCD) and neonatal intensive care unit (NICU) admission. Binomial regression and Kruskal Wallis tests were used to compare perinatal outcomes between the two cohorts in the general population and in a subgroup of those with isolated fasting hyperglycemia.

RESULTS

Outcomes for the "before" cohort (n = 1,733) were compared with those in the "after" cohort (n = 6,280). In the general population, A2GDM incidence increased after expansion of the screening protocol (4.8% vs. 6.4%, RR 1.34, 95% CI 1.07-1.69), but PCD and NICU admission rates were unchanged. In the subgroup of patients with isolated fasting hyperglycemia (n = 233), there was a significant increase in the incidence of any GDM (12.5 vs. 46.0%, RR 3.68, 95% CI 1.95-6.93) and A2GDM (8.3% vs. 37.3%, RR 4.47, 95% CI 2.03-9.87). There was no difference in PCD between cohorts, but NICU admission increased significantly in the "after" cohort (8.3% vs 22.4%, RR 2.68, 95% CI 1.18-6.08) in this subgroup.

CONCLUSION

An expanded approach to GDM diagnosis using home blood glucose monitoring following isolated fasting hyperglycemia on 3-hour GTT was associated with increased A2GDM incidence but no improvements in primary maternal or neonatal outcomes. In the absence of clinical benefit, we do not recommend widespread implementation of this expanded strategy.

Risk of adverse pregnancy outcomes after abnormal hysterosalpingography

OBJECTIVE

To investigate the association between an abnormal hysterosalpingogram (HSG) and obstetrical and neonatal outcomes.

DESIGN

A retrospective cohort study comparing outcomes between women with normal versus abnormal tubal patency and uterine cavity on HSG.

RESULTS

Among 2181 women included in the study, 494 (22.6%) had an abnormal HSG. Of these, 207 (42%) presented with uterine abnormalities, 336 (68%) with tubal abnormalities and 49 (10%) with both. The study identified 232 clinical pregnancies in the abnormal HSG group and 814 pregnancies in controls. Women with abnormal HSG showed higher rates of preterm labour (PTL) compared to controls (13.6% vs. 7.7%, p < 0.05, n = 1687). Multivariate analysis revealed that any HSG abnormality was associated with an increased risk of PTL (aOR 2.39, 1.04-5.51). When analysing by type of abnormality, uterine abnormalities increased the risk of preeclampsia (aOR 2.86, 1.06-7.7) and low birthweight (aOR 2.31, 1.0-5.35), while tubal abnormalities were specifically associated with increased risk of PTL (aOR 3.87, 1.63-9.19).

CONCLUSION

An abnormal HSG study was associated with adverse obstetrical outcomes. Specifically, uterine abnormalities increased the risk of preeclampsia and birthweight below 10th percentile, while tubal abnormalities were associated with a heightened risk of PTL.

Postpartum diabetes mellitus among patients with early gestational diabetes: A systematic review and meta-analysis

AIMS

It is unclear whether patients diagnosed with early gestational diabetes mellitus (GDM) (<24 weeks) are at higher risk of diabetes mellitus (DM) in the postpartum period compared to those with standard GDM (diagnosed ≥24 weeks). This study assessed if rate of DM diagnosed postpartum differs among patients with early versus standard GDM.

METHODS

PubMed, EMBASE, WHO ICTRP, Clinicaltrials.gov and Cochrane Central Register of Controlled Trials were searched from inception to March 2023. Randomized controlled trials or observational studies that assessed rate of postpartum DM among patients with early GDM were included. Primary outcome was rate of DM diagnosed postpartum. Secondary outcomes were postpartum visit attendance, completion and results of postpartum oral glucose tolerance testing, and glycated hemoglobin (HbA1c) levels.

RESULTS

Of 5682 studies screened, 11 met inclusion criteria (N = 1573 early GDM vs. N = 3340 standard GDM). Patients with early GDM had mean age of 30.2-37.0 years and mean body mass index (BMI) of 24.4-35.6 kg/m2, while the standard group had a mean age of 28.9-32.8 years and mean BMI of 23.6-36.0 kg/m2. Most studies evaluated postpartum glucose tolerance at 5-12 weeks, though one followed patients up to six years postpartum. Overall, patients with early GDM were more likely to be diagnosed with DM postpartum than those with standard GDM (12.8 % vs. 6.1 %, RR 1.89, 95 % CI 1.10-3.24). Impaired glucose tolerance was also higher in patients with early GDM (24.7 % vs. 13.0 %, RR 1.84, 95 % CI 1.32-2.57).

CONCLUSIONS

Rate of DM diagnosed postpartum was higher in patients with early GDM compared to standard GDM.

Perinatal Exercise and Cardiovascular Disease Risk

The purpose of this narrative review was to summarize perinatal exercise guidelines and associations of perinatal physical activity and/or exercise with cardiovascular disease (CVD) risk. Observational studies, randomized controlled trials, systematic reviews, and meta-analyses were included. Gaps in literature and suggestions for future studies were identified. Despite concordant international guidelines, data to support nuanced activity advice for some subgroups are limited. Perinatal physical activity and exercise are consistently recommended to combat traditional CVD risk factors during the perinatal period, like excessive gestational weight gain, high blood pressure, and high blood glucose. Physical activity and exercise appear to improve nontraditional risk factors such as poor sleep and depression. Data are emerging regarding associations with some pregnancy-specific factors, such as placental characteristics. Further research investigating associations with pregnancy-specific CVD risk factors and associations in the longer term, as well as data to support uptake, adherence, and resistance exercise prescription is warranted.

Association between glucose intolerance and fatty liver disease in women with previous gestational diabetes mellitus in urban Thailand: a prospective cohort study

OBJECTIVES

To examine the associations between glucose levels from the antepartum 100 g oral glucose tolerance test (OGTT) and the 6-week postpartum 75 g oral glucose tolerance test (OGTT) and fatty liver disease (FLD) at 1 year postpartum in women with a history of gestational diabetes mellitus (GDM).

DESIGN

A prospective cohort study.

SETTING

A tertiary hospital centre in Bangkok, Thailand.

PARTICIPANTS

A total of 130 women with a history of GDM who underwent liver fat assessment at 1 year postpartum.

OUTCOME MEASURES

FLD and metabolic dysfunction-associated steatotic liver disease were assessed at 1 year postpartum, with diagnosis based on transient elastography and specific cardiometabolic criteria. The associations between OGTT glucose values and FLD were evaluated using logistic regression models, adjusted for potential confounders, including age, pre-pregnancy weight, weight and waist circumference at 1 year postpartum and exclusive breastfeeding. Receiver operating characteristic analyses were also conducted to assess the predictive performance of glucose parameters from antepartum and postpartum OGTTs.

RESULTS

A total of 44 participants (33.8%) were diagnosed with FLD, with 97.7% meeting metabolic dysfunction-associated steatotic liver disease criteria. Elevated fasting plasma glucose levels during pregnancy (adjusted odds ratio (aOR): 1.49; 95% CI: 0.93 to 3.57), in the early postpartum period (aOR: 1.77; 95% CI: 0.92 to 5.05), or across both periods combined (aOR: 2.16; 95% CI: 0.93 to 7.41) were not independently associated with FLD. In contrast, four abnormal glucose values during pregnancy (aOR: 2.53; 95% CI: 1.03 to 7.87) and two abnormal values on the 6-week postpartum 75 g OGTT (aOR: 2.95; 95% CI: 1.06 to 11.20) were independently associated with FLD. The combined presence of abnormal OGTT values from both periods showed the strongest association with FLD (aOR: 3.04; 95% CI: 1.03 to 13.99), demonstrating high specificity (95.3%) but low sensitivity (13.6%).

CONCLUSIONS

Elevated glucose levels from the antepartum 100 g OGTT and the 6 week postpartum 75 g OGTT were associated with FLD at 1 year postpartum in women with a history of GDM. Comprehensive glucose monitoring during and after pregnancy may aid early identification of individuals at higher risk.

TRIAL REGISTRATION NUMBER

Thai Clinical Trials Registry: Registration no. TCTR20211027007. Date of registration: 27 October 2021. Date of initial participant enrolment: 1 November 2021.

Genetic architecture and risk prediction of gestational diabetes mellitus in Chinese pregnancies

Gestational diabetes mellitus, a heritable metabolic disorder and the most common pregnancy-related condition, remains understudied regarding its genetic architecture and its potential for early prediction using genetic data. Here we conducted genome-wide association studies on 116,144 Chinese pregnancies, leveraging their non-invasive prenatal test sequencing data and detailed prenatal records. We identified 13 novel loci for gestational diabetes mellitus and 111 for five glycemic traits, with minor allele frequencies of 0.01-0.5 and absolute effect sizes of 0.03-0.62. Approximately 50% of these loci were specific to gestational diabetes mellitus and gestational glycemic levels, distinct from type 2 diabetes and general glycemic levels in East Asians. A machine learning model integrating polygenic risk scores and prenatal records predicted gestational diabetes mellitus before 20 weeks of gestation, achieving an area under the receiver operating characteristic curve of 0.729 and an accuracy of 0.835. Shapley values highlighted polygenic risk scores as key contributors. This model offers a cost-effective strategy for early gestational diabetes mellitus prediction using clinical non-invasive prenatal test.

Even low levels of anticardiolipin antibodies are associated with pregnancy-related complications: A monocentric cohort study

INTRODUCTION

Moderate and high levels of anticardiolipin antibodies (aCL), especially in the setting of the antiphospholipid syndrome, are associated with adverse obstetric outcomes. However, the clinical relevance of low aCL levels (<40 MPL/GPL units) is still a matter of debate. The aim of the study was to evaluate obstetric outcomes in pregnancies with low immunoglobulin M (IgM) and/or immunoglobulin G (IgG) aCL positivity. The association between low aCL positivity and maternal baseline characteristics was also studied.

MATERIAL AND METHODS

The retrospective monocentric cohort study of prospectively collected data involved a total 3047 singleton pregnancies that underwent the first-trimester screening involving an aCL test and delivered on site. Obstetric outcomes were compared between the low-titer aCL group (IgM ≥7 MPL units and <40 MPL units and/or IgG ≥10 GPL units and <40 GPL units) and the aCL negative group (IgM <7 MPL units and IgG <10 GPL units, reference group). In addition, obstetric outcomes were evaluated with regard to the antibody isotype: IgM-positive group (IgM <40 MPL units, IgG negative) and IgG-positive group (IgG <40 GPL units, IgM negative or <40 MPL units).

RESULTS

Overall, the occurrence of pregnancy-related complications was significantly higher (27.91% vs. 19.32%, p = 0.034) in the low-titer aCL group. Concerning the antibody isotype, a higher rate of pregnancy-related complications was observed in the IgG-positive group (54.55% vs. 19.32%, p = 0.001), but not in the IgM-positive group (22.43% vs. 19.32%, p = 0.454). The stillbirth rate did not reach statistical significance. Low-titer aCL pregnancies were more frequently of advanced maternal age (p < 0.001), suffered from autoimmune diseases (p < 0.001), chronic hypertension (p = 0.040), and hereditary thrombophilia (p = 0.040). In addition, they had more often a positive history of stillbirth (p < 0.001), underwent conception via assisted reproductive technologies (p < 0.001), were administered low-dose aspirin (p < 0.001), low-molecular-weight heparin (p = 0.018) and immunomodulatory drugs (p < 0.001), and delivered earlier (p = 0.018).

CONCLUSIONS

Even low aCL levels are associated with a higher incidence of pregnancy-related complications, but only in the case of IgG antibody isotype presence. Screening for aCL in the first trimester has some prognostic value, but further studies are needed to determine whether its potential implementation into routine clinical practice would improve antenatal care.

Diagnostic Performance of a Type III Portable Monitoring Device for Obstructive Sleep Apnea in Pregnant Women: A Prospective Validation Study

Rationale: Obstructive sleep apnea (OSA) during pregnancy is linked to negative maternal and neonatal outcomes. Diagnosing OSA in this population is particularly challenging. Portable monitoring devices (PMD) present a potential alternative to polysomnography (PSG), but their effectiveness in pregnant women is uncertain. Objective: To evaluate diagnostic accuracy of a PMD to detect OSA in pregnant women. Methods: A prospective study of 136 middle-aged pregnant women (34 ± 4 years) in their third trimester of pregnancy (34 ± 3 weeks) who underwent laboratory type III PMD and PSG simultaneously. Results: Using an apnea-hypopnea index (AHI) ≥5 event/h by PSG, OSA was diagnosed in 10.3% of women (mild OSA: 86%; moderate OSA: 14%). An acceptable positive correlation was found between both tests in the AHI (r = 0.787; p < 0.001) and oxygen desaturation index (ODI) (r = 0.806; p < 0.001). The agreement limits between PSG and type III PMD were -4.1 to 5.4 for AHI and -6.0 to 4.5 for ODI. The sensitivity and specificity of type III PMD for an AHI ≥5 events/h were 57.1% and 99.2%, respectively, with a positive predictive value (PPV) of 88.9% and a negative predictive value (NPV) of 95.3%. On a receiver operating characteristic curve, the best cutoff point of AHI by type III PMD to identify OSA according to PSG criteria was 2.25 events/h. The sensibility and specificity for this point were 85.7% and 88.5%, respectively, with a PPV of 46.2% and NPV of 98.2%. Conclusions: A type III PMD with an AHI cutoff of 5 events/h could be a good alternative for OSA diagnosis in pregnant women. Additionally, an AHI ≥2.25 event/h demonstrates good diagnostic performance, but its low positive predictive value suggests that it is more appropriate as a screening tool. Further studies are needed to validate this sleep study tool in pregnant women, particularly in home settings.

Genetic effects on gestational diabetes mellitus and their interactions with environmental factors among Japanese women

Gestational diabetes mellitus (GDM) is common in Japanese women, posing serious risks to mothers and offspring. This study investigated the influence of maternal genotypes on the risk of GDM and examined how these genotypes modify the effects of psychological and dietary factors during pregnancy. We analyzed data from 20,399 women in the Tohoku Medical Megabank Project Birth and Three-Generation Cohort. Utilizing two customized SNP arrays for the Japanese population (Affymetrix Axiom Japonica Array v2 and NEO), we performed a meta-analysis to combine the datasets. Gene-environment interactions were assessed by modeling interaction terms between genome-wide significant single nucleotide polymorphisms (SNPs) and psychological and dietary factors. Our analysis identified two SNP variants, rs7643571 (p = 9.14 × 10-9) and rs140353742 (p = 1.24 × 10-8), located in an intron of the MDFIC2 gene, as being associated with an increased risk of GDM. Additionally, although there were suggestive patterns for interactions between these SNPs and both dietary factors (e.g., carbohydrate and fruit intake) and psychological distress, none of the interaction terms remained significant after Bonferroni correction (p < 0.05/8). While nominal significance was observed in some models (e.g., psychological distress, p = 0.04), the data did not provide robust evidence of effect modification on GDM risk once adjusted for multiple comparisons. These findings reveal novel genetic associations with GDM in Japanese women and highlight the importance of gene-environment interactions in its etiology. Given that previous genome-wide association studies (GWAS) on GDM have primarily focused on Western populations, our study provides new insights by examining an Asian population using a population-specific array.

Understanding the potential contribution of polygenic risk scores to the prediction of gestational and type 2 diabetes in women from British Pakistani and Bangladeshi groups: a cohort study in Genes and Health

Background

British Pakistani and Bangladeshi (BPB) women have disproportionately high rates of gestational diabetes mellitus (GDM), with prevalence estimates up to three times higher than in the general population. They are also at increased risk of progressing to type 2 diabetes, leading to significant health complications. Despite this, predictive models tailored to this high-risk, yet understudied group are lacking.

Objective

To investigate whether combining genetic and traditional clinical data improves risk prediction of GDM and progression to type 2 diabetes among BPB women. We hypothesized that incorporating polygenic risk scores (PRS) would enhance the predictive accuracy of existing models.

Study Design

An observational cohort study utilizing the Genes & Health dataset, which includes comprehensive electronic health records. Women who gave birth between 2000 and 2023, both with and without a history of GDM, were included. Controls were defined as women without a GDM diagnosis during this period but who had a birth record. A total of 117 type 2 diabetes or GDM PRS were tested to determine the optimal PRS based on predictive performance metrics. The best-performing PRS was integrated with clinical variables for statistical analyses, including descriptive statistics, chi-square tests, logistic regression, and receiver operating characteristic curve analysis.

Results

Of 13,489 women with birth records, 10,931 were included in the analysis, with 29.3% developing GDM. Women with GDM were older (mean age 31.7 years, P<.001) and had a higher BMI (mean 28.4 kg/m2, P<.001) compared to controls. The optimal PRS demonstrated a strong association with GDM risk; women in the highest PRS decile had significantly increased odds of developing GDM (OR 5.66, 95% CI [4.59, 7.01], P=3.62×10-58). Furthermore, the risk of converting from GDM to type 2 diabetes was 30% in the highest PRS decile, compared to 19% among all GDM cases and 11% in the lowest decile. Incorporating genetic risk factors with clinical data improved the C-statistic for predicting type 2 diabetes following GDM from 0.62 to 0.67 (P=4.58×10-6), indicating better model discrimination.

Conclusion

The integration of genetic assessment with traditional clinical factors significantly enhances risk prediction for BPB women at high risk of developing type 2 diabetes after GDM. These findings support the implementation of targeted interventions and personalized monitoring strategies in this high-risk population. Future research should focus on validating these predictive models in external cohorts and exploring their integration into clinical practice to improve health outcomes.

Targeting risk factors for false-positive outcomes in newborn hearing screening: a focus on mode of delivery - a case-control study

PURPOSE

Otoacoustic emission (OAE) is a widely utilized method for screening newborns for congenital hearing loss. While OAE-based screening has high sensitivity, it is associated with high false-positive rates when conducted shortly after birth. Previous studies found that infants delivered by cesarean section show higher false-positive rates. Nonetheless, other modes of delivery have not been investigated to date. This study aims to evaluate the impact of maternal, neonatal, and perinatal factors on hearing screening false-positive results.

METHODS

This retrospective study included 5,621 infants with normal hearing. Infants were divided into two groups: those who failed the initial OAE hearing screening were assigned to the study group, and those who passed were assigned to the control group. Maternal, neonatal, and perinatal factors were extracted from medical records and analyzed to assess possible associations with failing the initial OAE screening.

RESULTS

A total of 365 out of 5621 (6.5%) neonates failed the initial OAE hearing screening. The study group had a higher prevalence of infants delivered by elective or emergency cesarean section, as well as by vacuum-assisted delivery, compared to the control group. Multivariate analysis showed that the mode of delivery had a significant effect on false-positive results, with odds ratios of 15.5, 7.2, and 8.6 for infants born by elective cesarean section, emergency cesarean section, and vacuum delivery, respectively, compared to vaginal delivery.

CONCLUSION

Infants delivered by cesarean section or vacuum extraction have higher odds of failing the initial OAE screening when conducted within 48-72 h after birth. Further research is needed to determine the optimal timing for hearing screening.

The Association of Adverse Perinatal Outcomes in Pregnancies with Gestational Diabetes and Excessive Gestational Weight Gain According to Obesity Status

Obesity, gestational diabetes mellitus (GDM), and excessive gestational weight gain (EGWG) are associated with adverse outcomes. It is unclear which carries the greatest risk. In this study, the relationship of obesity, GDM, and EGWG independently and concomitantly was analyzed to determine if one is a greater risk factor than the other.A retrospective cohort study of singleton gestations at Geisinger from October 2007 to March 2023 was performed. Exclusion criteria were pregravid body mass index (BMI) <18 kg/m2, gestational age (GA) <34 weeks, pregestational diabetes or chronic hypertension, prior cesarean delivery (CD) or contraindication to vaginal delivery. Patients were grouped by BMI class, and the order of groups within each BMI for the test for trend were no GDM/no EGWG, GDM/no EGWG, no GDM/EGWG, and GDM/EGWG. The rates of hypertensive disorders of pregnancy (HDP), severe HDP, CD, large for gestational age (LGA), shoulder dystocia, and neonatal intensive care unit (NICU) admission at ≥35 weeks were evaluated. A test for trend and odds ratios with 95% CIs were reported. p-values were reported across the GDM/EGWG groups per BMI category.A total of 42,627 pregnancies were included. At each BMI category, HDP, severe HDP, CD, LGA, and shoulder dystocia generally increased from patients with no GDM/no EGWG to those with GDM/no EGWG to those with no GDM/EGWG to those with GDM/EGWG. NICU admission at ≥35 weeks did not follow this progression.EGWG poses a greater risk than GDM regardless of pregravid BMI for HDP, severe HDP, CD, LGA, and shoulder dystocia. Attention should be given to determine the optimal strategy to manage pregnancies experiencing EGWG. · Isolated EGWG in pregnancy is associated with a greater risk of targeted maternal adverse outcomes.. · The combination of EGWG, GDM, and obesity poses the greatest risk during pregnancy.. · Attention should be given to determining the optimal role for antenatal surveillance for patients with EGWG..

Association of the Triglyceride-Glucose Index During the First Trimester of Pregnancy with Adverse Perinatal Outcomes

Background/Objectives: Insulin resistance during pregnancy is a key factor underlying gestational diabetes mellitus (GDM) and other adverse perinatal outcomes (APOs). While traditional markers, such as HOMA-IR, are used to evaluate insulin resistance, they may be inaccessible in resource-limited settings. The triglyceride-glucose (TyG) index has emerged as a practical alternative. This study aimed to assess whether or not a TyG index > 8.6 during the first trimester of pregnancy is associated with an increased risk of APOs, including GDM, preeclampsia, and other maternal and neonatal complications. Methods: A prospective cohort study was conducted involving 333 pregnant women in Mexico City, divided into two groups: Group 1 (TyG index > 8.6, n = 153) and Group 2 (TyG index ≤ 8.6, n = 180). Primary outcomes included gestational diabetes mellitus (GDM), hypertensive disorders of pregnancy, preeclampsia, preterm birth, cesarean section, and large-for-gestational-age (LGA) and small-for-gestational-age (SGA) neonates. Logistic regression models were used to calculate the adjusted relative risk (aRR) and 95% confidence intervals (CIs), adjusting for maternal age, pregestational weight, and body mass index (BMI). Results: Women with a TyG index > 8.6 had a significantly higher pregestational weight and BMI than those with a TyG index ≤ 8.6. Group 1 demonstrated a higher risk of GDM (RR 2.05; 95% CI: 1.23-3.41) and preeclampsia (RR 2.15; 95% CI: 1.10-4.21). After adjusting for maternal age, pregestational weight, and BMI, these associations remained significant: GDM (aRR 1.87; 95% CI: 1.0-2.5) and preeclampsia (aRR 2.18; 95% CI: 1.1-5.0). No significant associations were found between an elevated TyG index and other APOs, including LGA, SGA, preterm birth, or cesarean delivery. Conclusions: A first-trimester TyG index > 8.6 is significantly associated with an increased risk of GDM and preeclampsia, highlighting its potential as a predictive marker for adverse perinatal outcomes. These findings underscore the utility of the TyG index as a practical, cost-effective tool for early risk stratification, particularly in resource-limited settings. Further multi-center research is needed to validate these results and refine population-specific thresholds.

Evaluation of ketones intensive measurement in women with gestational diabetes (EVOKING) study

PURPOSE

Women with gestational diabetes mellitus (GDM) are frequently asked to check their ketone levels by measuring ketonuria before breakfast. However, ketosis could be present even before lunch and dinner. Furthermore, blood ketone measurement could be a more accurate test. Our aim was to evaluate the effect of a blood ketone intensive measurement in the detection of ketosis in women with GDM with a negative urinary ketone test.

METHODS

This was a single center, observational, prospective study involving consecutive women with GDM. Only women with negative fasting urinary ketone tests were included. During the same gestational weeks (weeks 30-32), all women were asked to perform a blood ketone test before their main meals. Ketosis was defined as the presence for at least 25% of the time of fasting blood ketone levels > 0.1 mmol/L and > 0.2 mmol/L before lunch and dinner.

RESULTS

Overall, a total of 101 women (mean age 34.7 ± 4.8 years, prepregnancy BMI 28.2 ± 5.2 kg/m2) were studied. Blood ketones were present in 37.6% of the cases before breakfast, 13.9% before lunch, and 11.9% before dinner. Women with at least one daily presence of blood ketones composed 40.6% of the sample. Presence of fasting blood ketones was correlated with ketone presence before lunch (r = 0.63, p < 0.0001) and before dinner (r = 0.55, p < 0.0001) and with mean glucose levels (r = 0.23, p = 0.02) 1 h after breakfast.

CONCLUSION

Blood ketone testing in women with GDM can detect a larger number of ketosis episodes than a urinary ketone test. Intensive blood ketone measurement should be recommended to women with GDM.

Fertility-Enhancing Potential of P. amygdalas and J. regia Oil Mixture in Wistar Rats: Male/Female Infertility Models Assessment

Polyunsaturated fatty acids-rich nuts are a group of natural sources that have served as a tonic in the treatment of many ailments for centuries. In this regard, P. amygdalas and J. regia nuts are traditionally used in infertility treatments. However, so far, the main mechanisms for the fertility-enhancing effects of these nuts in males/females are unknown. The present study was intended to evaluate the fertility-boosting effect of a mixture constituting P. amygdalas and J. regia oil on male/female infertility models and in two successive generations of rats; F 0 (parents) and F 1 (offspring). For the fertility assessment, male and female rats, 18 pairs (n = 36, 1:1, F 0 generation), were separated into three groups and dosed with 2 and 4 mL/kg daily of oil mixture and saline, respectively, from precohabitation up to lactation. To determine the further protective role of the oil mixture in infertility, we designed ethanol-induced male and estradiol-induced female infertility models. Various parameters like hormonal, hematological, lipid profile, and antioxidant markers [superoxide dismutase (SOD), glutathione peroxidase (GPx)] were measured along with histopathology of sex organs. The continual exposure of F 0 and F 1 generations to the oil mixture did not affect the fertility index and survival index in females. However, in males, all sperm parameters were significantly improved in both generations. We have found pronounced fertility outcomes with oil mixture supplementation in both genders of F 0 and F 1 generations. Results showed that the oil mixture significantly restored (p < 0.05) luteinizing hormone (LH), follicular stimulating hormone, GPx, plasma testosterone, and SOD activities in both models. Histological findings endorsed enhanced folliculogenesis and spermatogenesis with enhanced architecture. Our results strongly suggest that P. amygdalas and J. regia oil mixture might be a promising option in future for male/female sterility treatment. This finding could pave the way in infertile men and women for clinical trials. This is the first study that has provided an experimental rationale for a walnut and almond oil mixture combination as an effective candidate for fertility recovery by improving sex hormones and managing oxidative stress.

Guidelines for antenatal and preoperative care in cesarean delivery: Enhanced Recovery After Surgery Society recommendations (part 1)-2025 update

BACKGROUND

Enhanced recovery after cesarean delivery protocols include evidence-based interventions designed to improve patient experience, pregnancy, and neonatal outcomes while reducing healthcare-related costs. This is the first update of the Enhanced Recovery After Surgery Society guidelines for antenatal and preoperative care before cesarean delivery after the original publication in 2018.

METHODS

Interventions were selected based on expert consensus using the Delphi method. An updated literature search was conducted in September 2024 using the Embase, PubMed, MEDLINE, EBSCO CINAHL (Cumulative Index of Nursing and Allied Health Literature), Scopus, and Web of Science databases. Targeted searches were performed by a medical librarian to identify relevant articles published since the 2018 Enhanced Recovery After Surgery Society guidelines publication, which evaluated each antenatal and preoperative enhanced recovery after cesarean delivery intervention, focusing on randomized clinical trials and large observational studies (≥800 patients) to maximize search feasibility and relevance. Following a review of the evidence, a consensus was reached regarding the quality of evidence and the strength of recommendation for each proposed intervention according to the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system.

RESULTS

The 6 recommended enhanced recovery after cesarean delivery interventions are (1) antenatal pathway patient education for scheduled caesarean delivery (evidence low to very low, recommendation strong); (2) multidisciplinary medical and surgical staff education regarding enhanced recovery after cesarean delivery support, intervention implementation, and measurement (evidence low, recommendation strong); (3) optimization of the medical care for pregnant patients with comorbid conditions, such as anemia, obesity, hypertension, prepregnancy and gestational diabetes, smoking (tobacco, cannabis, vaping), congenital heart disease, epilepsy, autoimmune disease, and asthma (evidence moderate, recommendation strong); (4) abdominal skin preparation with chlorhexidine gluconate impregnated cloth (evening before scheduled cesarean delivery) (evidence moderate; recommendation weak); (5) the duration of preoperative fasting based on the content intake (evidence low, recommendation weak); (6) the use of a preoperative, nonparticulate carbohydrate drink (evidence low-moderate, recommendation strong).

CONCLUSION

The first 3 recommendations are for use in the antenatal period (10-38 weeks of gestation), which allow for the optimization of patient comorbidities, whereas the remaining 3 recommendations are for preoperative interventions (skin preparation, preoperative fasting directives, and preoperative carbohydrate supplementation). Educational tools for cesarean delivery with well-designed shared decision-making focus on comorbidity management should be developed. These management tasks are viewed as routine care; however, the measurable success and impact have clinical variance. The enhanced recovery after cesarean delivery goal for patients who are undergoing a scheduled caesarean delivery is to maximize the quality of the pregnant patient's recovery and the fetal-neonatal outcome.

Predictors of small-for-gestational-age infants in gestational diabetes mellitus: the impact of metformin use

INTRODUCTION

Gestational diabetes mellitus (GDM) affects 3%-25% of pregnancies worldwide, posing risks to maternal, fetal, and neonatal health. GDM is often associated with macrosomia and large-for-gestational-age (LGA) infants. However, the association between GDM and small-for-gestational-age (SGA) infants is less understood. This study aimed to identify predictors of SGA in women with GDM.

METHODS

This retrospective study included GDM patients (GDMA1 and A2) admitted to the fetal-maternal unit between 2014 and 2023. The study population was divided into those who delivered an appropriate for gestational age (AGA) neonate and those who delivered an SGA neonate (defined as birthweight < 10th percentile. Women with pregestational diabetes mellitus were excluded. Obstetric and neonatal outcomes were compared between the groups. A subgroup analysis focused on GDMA2 patients, comparing maternal and neonatal outcomes and treatment regimens (insulin and metformin use).

RESULTS

The study included 894 GDM patients. Compared to the AGA group (n = 712), the SGA group (n = 182) had lower maternal BMI (p = 0.02). Maternal age was comparable between groups. Rates of GDMA2 (30.2% vs. 23.4%, p = 0.07), and hypertensive disorders (7.1% vs. 5%, p = 0.21) did not differ significantly between the groups. The neonatal birthweight of the SGA infants was 2375 ± 432 g vs. 3021 ± 165 g in the AGA infants, (p = 0.005). The SGA group had a higher rate of CD due to NRFHR (27.4% vs. 18.4%, p < 0.01). Among GDMA2 patients (n = 222), more women in the SGA group (n = 55) were treated with metformin as compared to the AGA group (n = 167) (72.7% vs. 23.9%, p < 0.001). Multivariate regression analysis revealed that among GDMA2 patients metformin treatment was independently associated with SGA neonates OR 1.7, CI 1.18-1.35, p < 0.01).

CONCLUSION

Metformin use in GDMA2 pregnancies may be linked to SGA neonates. The impact of metformin on fetal growth highlights the need for careful monitoring and individualized treatment strategies in managing GDMA2.

Association of Prepregnancy Obesity versus Excessive Gestational Weight Gain with Adverse Maternal Outcomes in the United States

Prepregnancy body mass index (BMI) >30 kg/m2 or prepregnancy obesity (PPO) and excessive gestational weight gain (eGWG) are associated with increased risks for adverse maternal outcomes. There is little is known regarding the individual effects of PPO and eGWG. The objective of this study was to compare the effects of PPO and eGWG with adverse maternal outcomes.This was a retrospective cohort study of singleton, live births in the United States in 2018 using data from the National Vital Statistics System. Pregnancies complicated by pregestational diabetes, chronic hypertension, and with unknown maternal BMI were excluded. Institute of Medicine recommendations were used to define gestational weight gain (GWG). These births were divided into four groups: (1) normal prepregnancy BMI and normal GWG, (2) normal prepregnancy BMI and eGWG, (3) PPO and normal GWG, and (4) PPO and eGWG. Outcomes such as gestational diabetes, hypertensive disorders of pregnancy, cesarean delivery, maternal transfusion, and medical intensive care unit admissions were compared among groups using analysis of variance and multivariable logistic regression analysis.Of the 1,432,602 births included in the study, 22.2, 42.3, 10.1, and 25.4% were in Groups 1 to 4, respectively. Compared with pregnancies in Group 1 (adjusted odds ratio [95% confidence interval]), Groups 3 and 4 had higher risk for gestational diabetes (2.80 [2.72-2.88] and 2.28 [2.22-2.34]), respectively, whereas Groups 2 to 4 had higher risk of hypertensive disease of pregnancy (1.58 [1.53-1.64], 3.88 [3.74-4.03], and 5.07 [4.90-5.23]); eclampsia (1.61 [1.33-1.95], 2.99 [2.42-3.69], and 3.57 [2.97-4.29]), and cesarean delivery (1.21 [1.19-1.23], 1.97 [1.92-2.02], and 2.45 [2.40-2.50]), respectively.Both PPO and eGWG are independently associated with higher odds of gestational diabetes, gestational hypertension, preeclampsia, and cesarean sections, with the highest risk among pregnancies with both PPO and eGWG. These data support the importance of prepregnancy weight management in preventing adverse pregnancy outcomes. · Maternal obesity is associated with adverse maternal outcomes.. · Maternal obesity is due to PPO or eGWG.. · To study the contribution of adverse maternal outcomes by PPO as distinct from eGWG..

The Role of the Intrauterine Environment in Shaping Childhood and Adolescence Metabolic Outcomes

Emerging research suggests that the intrauterine environment plays a critical role in predisposing individuals to metabolic syndrome (MetS), a constellation of conditions that heightens the risk for heart disease, stroke, and diabetes. Traditionally linked to lifestyle, the risk for MetS is now understood to be also influenced by fetal exposures. The environment in which a child lives offers abundant potential sources that can contribute to an increased risk of developing various diseases, and in some cases, these factors can be avoided. This review integrates findings from both epidemiological and experimental research to underscore the impact of prenatal factors, including maternal nutrition, obesity, gestational diabetes (GDM), and birth size, on the subsequent development of metabolic derangements in offspring, particularly during puberty. The progression of genetic and epigenetic studies has enlightened the pathophysiology of these conditions starting in the intrauterine period and continuing into early life. By examining data and studies, this article elucidates the prenatal influences and underlying mechanisms that contribute to the pathogenesis of MetS. The updated understanding of the link between the intrauterine environment and future health comorbidities will draw attention to intrauterine care and maternal health and contribute to the prevention of serious diseases in adulthood.

Effect of in utero metformin exposure in gestational diabetes mellitus on infant mesenchymal stem cell metabolism

Offspring exposed to metformin treatment for gestational diabetes mellitus (GDM) experience altered growth patterns that increase the risk for developing cardiometabolic diseases later in life. The adaptive cellular mechanisms underlying these patterns remain unclear. Therefore, the objective of this study was to determine whether chronic in utero metformin exposure associated with GDM treatment elicits infant cellular metabolic adaptations. In a cross-sectional design, 22 pregnant women diagnosed with GDM and treated exclusively with metformin (Met; n = 12) or diet (A1DM; n = 10) were compared. Umbilical cord-derived mesenchymal stem cells (MSCs) were used as a model to study infant metabolism in vitro. OXPHOS and citrate synthase content were assessed by Western blot and intracellular lipid content was measured by Oil Red-O staining. Substrate oxidation and insulin action were measured with 14C radiolabeled glucose and oleate at baseline and following a 24-h lipid challenge. Mitochondrial respiration was assessed by high-resolution respirometry. Although no differences in infant birth measures were observed between groups, MSC outcomes revealed lower oleate oxidation rates (P = 0.03) and lower mitochondrial capacity (P = 0.009) among Met-MSCs. These findings suggest differences in energy metabolism may be present at birth among offspring exposed to metformin in utero. Lower oleate oxidation and mitochondrial capacity in infant MSC may contribute to altered growth patterns that have been reported among offspring of metformin-treated pregnant women with GDM.NEW & NOTEWORTHY Mesenchymal stem cells (MSCs) of infants born to women with gestational diabetes mellitus (GDM) treated by metformin display lower rates of oleate oxidation despite no limitations in lipid availability compared with GDM treated by diet. Mitochondrial capacity was also lower among infant MSCs from metformin-treated GDM.

Comparison of Ultrasound Findings Associated with Adverse Fetal, Obstetric, and Neonatal Outcomes in Pregestational Type 1 And Type 2 Diabetes: A Systematic Review

We aimed to summarize the available evidence examining the association between prenatal ultrasound findings and adverse fetal, obstetric, and neonatal outcomes in pregnancies complicated by type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) and to evaluate whether the predictive value of ultrasound findings for adverse outcomes varies between T1DM and T2DM pregnancies.We conducted a systematic review of the existing literature through August 12, 2024. We included articles in English that reported associations between ultrasound findings and fetal, obstetric, and neonatal outcomes in pregnant people with T1DM and T2DM. The primary outcome of interest was stillbirth; secondary outcomes were neonatal demise, neonatal intensive care unit admission, neonatal hypoglycemia, respiratory distress syndrome, polycythemia, hyperbilirubinemia, organomegaly, electrolyte disturbances, shoulder dystocia, permanent brachial plexus injury, cord gas, Apgar scores, large for gestational age (LGA), small for gestational age (SGA), and preterm birth. Two independent reviewers examined articles at the abstract level and, if eligible, at the full-text level; disagreements were adjudicated by a third reviewer.Of the 2,088 unique citations reviewed, 12 studies met the inclusion criteria describing associations between ultrasound findings and fetal, obstetric, and neonatal outcomes among a total of 1,165 pregnant people with T1DM and 489 pregnant people with T2DM. Most studies (10/12) examined the association between ultrasound measures of growth, including estimated fetal weight and its individual components, abdominal wall thickness, head circumference to abdominal circumference ratio, and birth weight, LGA or SGA. Studies did not examine stillbirth, neonatal demise, or maternal outcomes other than cesarean section.This systematic review synthesizes the available literature on ultrasound risk markers of adverse fetal, obstetric, and neonatal outcomes separately in pregnant people with T1DM and T2DM. We identified very few studies that distinguished between pregnant people with T1DM and T2DM, and the majority focused on surrogate outcomes (e.g., LGA, SGA) of morbidity. Our findings highlight the need for further studies investigating these distinct diseases to provide evidence for antenatal management recommendations. · This systematic review compares ultrasound risk markers for adverse outcomes in pregnancies with T1DM and T2DM.. · Few studies compare ultrasound risk markers for adverse outcomes among pregnancies with T1DM and T2DM.. · Additional targeted studies to inform antenatal ultrasound care are necessary..

Comparison of universal screening for gestational diabetes mellitus between one-step and two-step method among Thai pregnant women: A randomized control trial

AIMS

To compare the prevalence of GDM and pregnancy outcomes between the one-step and two-step methods of universal screening among Thai pregnant women.

METHODS

A randomized controlled trial was conducted on singleton Thai pregnant women at a gestational age of 24-28 weeks. They were randomly assigned to either the one-step method group (a universal 75-gm 2-h oral glucose tolerance test: OGTT) or the two-step method group (a universal 50-gm oral glucose challenge test followed by a 100-gm 3-h OGTT). The women received standard antenatal care. The prevalence of GDM and obstetric outcomes were compared.

RESULTS

A total of 143 women meeting the inclusion criteria were randomly allocated into the one-step group (72 cases) and the two-step group (71 cases). The prevalence of GDM was significantly higher in the one-step group than in the two-step group, with rates of 24/73 (33.3%) vs 8/70 (11.3%); P value 0.002; relative risk of 2.96, 95% CI: 1.43-6.14, respectively. Demographic data and maternal and neonatal outcomes were comparable between the two groups.

CONCLUSIONS

The one-step method can markedly increase the prevalence of GDM to nearly three times that of the two-step method, leading to a substantial increase in care costs and burdens without clear benefits. Convincingly, the one-step method as a new approach may not be suitable for universal screening in a busy antenatal care setting, especially in low-resource health centers in developing countries or among populations with a high prevalence of GDM.

Gestational diabetes mellitus - more than the eye can see - a warning sign for future maternal health with transgenerational impact

Gestational diabetes mellitus (GDM) is regarded by many as maternal maladaptation to physiological insulin resistance during the second half of pregnancy. However, recent evidence indicates that alterations in carbohydrate metabolism can already be detected in early pregnancy. This observation, the increasing prevalence of GDM, and the significant short and long-term implications for the mother and offspring call for reevaluation of the conceptual paradigm of GDM as a syndrome. This review will present evidence for the syndromic nature of GDM and the controversies regarding screening, diagnosis, management, and treatment.

A Pilot Study Using Continuous Glucose Monitoring among Patients with a Low 1-Hour Glucose Challenge Test Result versus Controls to Detect Maternal Hypoglycemia

A low 1-hour glucose challenge test (GCT) result (<10th percentile for population) has been associated with neonatal morbidity, including small-for-gestational-age birth weight, and it is hypothesized that underlying maternal hypoglycemia may contribute to this neonatal morbidity. We sought to assess whether eligible patients would undergo continuous glucose monitoring to allow comparison of maternal hypoglycemia between those with a low GCT result versus controls.This exploratory study enrolled patients who completed a GCT between 24 and 30 weeks' gestation from June to September 2022. English- or Spanish-speaking participants aged ≥18 years wore a blinded continuous glucose monitor (CGM) for 10 days. There were 10 participants each in the low GCT (<82 mg/dL) and normal GCT group. Proportions were calculated to determine recruitment rates and describe the low versus normal glycemic groups across clinical and sociodemographic characteristics. Maternal hypoglycemia, defined using various proposed thresholds, was analyzed as continuous data (time duration) with Student's t-tests and categorical data (number of episodes) with chi-square tests and bivariate analyses were performed comparing participants with a low versus normal GCT. Primary outcome measures were recruitment, enrollment, and adherence rates, and overall glycemic values for each group.Of 64 eligible patients, 58 (91%) were approached, and of them, 20 (35%) were enrolled. All 20 participants had CGM data to review with 100% adherence. Average glucose values were similar between participants in the low GCT and normal GCT groups (111.7 ± 18.0 vs. 111.6 ± 11.7 mg/dL, p = 0.99), and participants with a low GCT value did not demonstrate more hypoglycemia than those with a normal GCT value across five proposed thresholds on CGM analysis.In this pilot study, participants wore blinded CGMs to collect glycemic data, and those with a low GCT result did not experience more hypoglycemia than those with a normal GCT on CGM analysis. · Study participants wore continuous glucose monitors in blinded mode to gather glycemic data with 100% adherence.. · Participants with a low GCT result (<82 mg/dL) as compared with those with a normal GCT result were not more likely to demonstrate maternal hypoglycemia using several thresholds on CGM analysis.. · In our cohort, there were few participants in either glycemic group who reported food insecurity or lived in a food desert..

Association of early onset gestational diabetes mellitus with postpartum glucose intolerance

Background

This study aimed to investigate the association between postpartum glucose intolerance and the timing of gestational diabetes mellitus (GDM) diagnosis according to criteria from the International Association of Diabetes and Pregnancy Study Groups (IADPSG).

Methods

A single-center retrospective case-control study involving patients diagnosed with GDM according to IADPSG criteria was conducted. Patients underwent a postpartum 75 g oral glucose tolerance test (OGTT) and were divided into 2 groups: normal (control) and abnormal glucose tolerance (AGT). Gestational age at GDM diagnosis and the maternal and neonatal outcomes were compared between the groups.

Results

Data from 177 controls and 102 patients diagnosed with AGT were analyzed. The AGT group exhibited a higher pre-pregnancy body mass index, family history of diabetes, glycated hemoglobin level at the initial visit, and total daily insulin dose, but a lower rate of GDM diagnosis at 24-32 weeks' gestation. GDM diagnosed before 24 weeks' gestation was independently associated with AGT (adjusted odds ratio 2.18 [95% confidence interval 1.28-3.73]; p < 0.01]). Additionally, a higher proportion of patients diagnosed with GDM before 24 weeks' gestation had a lower disposition index (27.1% versus 14.8%; p = 0.01).

Conclusions

Patients diagnosed with GDM at < 24 weeks' gestation were at higher risk for postpartum glucose intolerance than those diagnosed at 24-32 weeks. The lower disposition index in patients early diagnosed highlights the need for tailored postpartum follow-up to address their specific risks.

Impact of maternal overweight/obesity and high fasting plasma glucose on adverse perinatal outcomes in early gestational diabetes mellitus

AIM

To elucidate risk factors associated with adverse perinatal outcomes in early-gestational diabetes mellitus (GDM).

MATERIALS AND METHODS

A dataset of 385 early-GDM cases from a prospective cohort was analyzed. Early-GDM was diagnosed if one or more of the following criteria were met: fasting plasma glucose (PG) levels of 92-125 mg/dL, 1-h PG levels ≥180 mg/dL, and 2-h PG levels ≥153 mg/dL during a 75-g oral glucose tolerance test before 20 weeks of gestation. Multivariate analysis was used to examine associations between candidate risk factors and a composite outcome of maternal and neonatal adverse events.

RESULTS

Pre-pregnancy overweight/obesity (pre-pregnancy body mass index [BMI] ≥25.0 kg/m2) was significantly associated with a higher risk of the composite outcome compared with normal weight (pre-pregnancy BMI of 18.5-24.9 kg/m2), an adjusted risk ratio (aRR) of 1.44 (95% confidence interval [CI]: 1.08-1.93), and an adjusted risk difference (aRD) of 13.6% (95% CI: 2.6-24.6%). Compared with fasting PG levels below 92 mg/dL, levels between 95 and 125 mg/dL were associated with a significantly higher risk of the composite outcome, with an aRR and aRD of 1.42 (95% CI: 1.01-1.99) and 12.9% (95% CI: 0.3-25.5%), respectively.

CONCLUSIONS

Early-GDM, combined with pre-pregnancy overweight/obesity and/or fasting PG levels of 95-125 mg/dL, is associated with a higher risk of adverse perinatal outcomes and should be prioritized for intervention.

Development and validation of gestational diabetes mellitus health behaviour scale

OBJECTIVE

We aimed to develop the health behaviour scale for gestational diabetes mellitus patients (HB-GDM) and evaluate its psychometric properties. The scale may provide theoretical basis and evidence for identifying the pathways to enhance health behaviours and optimise health management strategies.

METHODS

The initial constructs and items of the scale were developed through literature review, qualitative analysis and Delphi expert consultation based on the socio-ecological model. Item analysis was conducted by four methods and using a sample (n = 235) recruited in China to form formal scale. Additional participants (n = 505) completed survey to measure the internal consistency reliability, test-retest reliability, content validity, construct validity and criterion-related validity of scale.

RESULTS

The scale contains six dimensions with a total of 29 items. The Cronbach's α of the scale was 0.912, McDonald's ω of the scale was 0.936, test-retest reliability was 0.957, content validity was 0.935, The cumulative variance contribution rate of the six common factors was 77.488 % and CFA model had acceptable goodness-of-fit indices(χ2/df = 2.567, RMSEA = 0.079). The criterion-related validity was 0.827(P<0.01).

CONCLUSION

HB-GDM scale showed satisfactory psychometric properties and has strong specialisation and better applicability.

PRACTICE IMPLICATIONS

The scale is favourable for pregnant women with GDM to clarify their unhealth behaviours. It provided guidance regarding maternal and postpartum follow-up care and the formulation of women health care strategies with regional characteristics.

Physical Inactivity Among Pregnant Women at High Risk for Gestational Diabetes Mellitus: A Cross-Sectional Study

AIM

To examine the prevalence and predictors of physical inactivity among pregnant women at high risk for gestational diabetes mellitus (GDM) in mainland China.

METHODS

A cross-sectional study was implemented in Zhengzhou, China from October 2021 to February 2022. Two hundred fifty-two pregnant women at high risk for GDM were recruited. Physical inactivity was assessed by the Pregnancy Physical Activity Questionnaire. The Pregnancy Physical Activity Self-Efficacy Scale, Knowledge of Physical Activity Questionnaire, Social Support for Physical Activity Scale, 7-item Generalized Anxiety Disorder Scale, Edinburgh Postnatal Depression Scale and sociodemographic and antenatal characteristics questionnaire were collected and used to predict physical inactivity. Binary logistic regression was applied. Adjusted odds ratios and 95% confidence intervals (CIs) were calculated.

RESULTS

The prevalence of physical inactivity was 53.2%. The risk factors for physical inactivity included low level of physical activity self-efficacy (aOR: 6.05, 95% CI: 1.13-32.31), middle levels of physical activity self-efficacy (aOR: 5.13, 95% CI: 1.45-18.20), no pregnancy physical activity goals (aOR: 3.06, 95% CI: 1.18-8.0), low pregnancy physical activity goals (aOR: 2.64, 95% CI: 1.02-6.8), nulliparity (aOR: 7.17, 95% CI: 3.74-13.75), having a junior college degree or below (aOR: 2.03, 95% CI: 1.10-3.74) and husbands having no habits of regular physical activity (aOR: 2.07, 95% CI: 1.06-4.04).

CONCLUSION

This study revealed that physical inactivity among pregnant women at high risk for GDM was a public health concern in mainland China. Physical activity self-efficacy and pregnancy physical activity goals may be used to develop interventions to enhance physical activity.

Diabetes and pregnancy: A call for terminology standardization in clinical practice

Currently, there is no unified consensus on the terminology used to describe diabetes in the context of pregnancy, leading to confusion among clinicians and challenges in research. This review article proposes a set of terms to classify diabetes during pregnancy based on timing and diagnostic criteria, whether before or during pregnancy. A review of previous documents addressing terminology and classification was conducted, identifying four main terms: (1) pregestational diabetes mellitus, referring to diabetes diagnosed before pregnancy; (2) early gestational diabetes mellitus, diagnosed before 24 weeks of gestation; (3) late gestational diabetes mellitus, diagnosed at or after 24 weeks of gestation; and (4) diabetes in pregnancy, diagnosed at any gestational age. This proposal does not include an analysis of hyperglycemia's pathophysiological mechanisms or specific diagnostic criteria. The proposed classification could serve as a foundation for a global initiative to establish a consensus on terminology for diabetes in pregnancy. A universally accepted terminology would reduce clinical confusion, provide a framework for defining diagnostic criteria, facilitate research on maternal and fetal complications, and support studies exploring the postpartum progression of diabetes.

Utility of maternal A1c measurement in the second trimester for the diagnosis of gestational diabetes mellitus

BACKGROUND

To investigate the effectiveness of maternal hemoglobin A1c (HbA1c) in the diagnosis of gestational diabetes mellitus (GDM) in the second trimester.

METHODS

A total of 3000 pregnant women between 24 and 28 weeks of gestation were included in the study. Screening for gestational diabetes was performed using maternal HbA1c in 1200 pregnant women who either refused or could not tolerate the OGTT. The HbA1c value for the diagnosis of GDM was set at ≥ 5.7% in accordance with a meta-analysis by Paula B. Renz et al. A total of 154 pregnant women with HbA1c ≥ 5.7% were diagnosed with gestational diabetes, and their data were recorded prospectively. These data were compared with obstetric outcomes in 250 pregnant women diagnosed with diabetes by performing a 100-g OGTT after a 50-g glucose challenge test (GCT).

RESULTS

There were no significant differences between two groups in terms of maternal age, gestational age at diagnosis, gravidity, and parity. Body mass index (BMI) was found to be significantly higher in pregnant women with HbA1c levels ≥ 5.7% (p < 0.001). Polyhydramnios was more common in the HbA1c ≥ 5.7% group and oligohydramnios was more common in the OGTT group (p < 0.001). Neonatal hypoglycemia was found to be significantly higher in the OGTT group (p < 0.05). The median HbA1c value were different in each group (OGTT group 5.6%, HbA1c group 5.8%; p < 0.001).

CONCLUSION

HbA1c testing has lower accuracy rates than OGTT in diagnosing GDM because it may miss diagnosis in some groups.

Psychosocial, Behavioral, and Medical Drivers of Gestational Diabetes among Racial-Ethnic Groups

Certain racial and ethnic groups have historically been labeled "high-risk" for the development of gestational diabetes mellitus (GDM). Our objective was to identify the psychosocial, behavioral, and medical factors associated with GDM and determine if they differ by race/ethnicity.Secondary analysis of a multicenter, prospective cohort study of pregnant nulliparous individuals with singleton gestations (2010-2013). The primary outcome was GDM. Psychosocial, behavioral, and medical characteristics were compared by self-reported race/ethnicity. Multivariable logistic regression with backward selection identified factors associated with GDM. Interaction terms between race/ethnicity and risk factors were tested.Of 8,672 pregnant individuals, 61% were non-Hispanic White, 13% non-Hispanic Black, 17% Hispanic, 4% Asian, and 5% other. The incidence of GDM differed by race/ethnicity with 4% non-Hispanic White, 3% non-Hispanic Black, 5% Hispanic, 11% Asian, and 5% other (p < 0.001). Of 34 psychosocial, behavioral, and medical factors, those associated with GDM were parent with history of diabetes (adjusted odds ratio [aOR]: 1.72; 95% confidence interval [CI]: 1.33-2.23), non-English language (aOR: 2.57; 95% CI: 1.14-5.79), daily calorie intake (aOR: 1.18; 95% CI: 1.08-1.29), daily fiber intake (aOR: 0.84; 95% CI: 0.75-0.94), maternal age (aOR: 1.53; 95% CI: 1.37-1.70), prepregnancy BMI (aOR: 1.21; 95% CI: 1.02-1.44), and waist circumference (aOR: 1.21; 95% CI: 1.03-1.43). These associations did not differ based on race/ethnicity (interaction p-values > 0.1).Replacing race/ethnicity as a risk factor for GDM with significant upstream psychosocial, behavioral, and medical factors should be considered. · GDM varies in incidence based on race.. · GDM was linked to a parent with various factors.. · These factors are the history of diabetes, non-English language, and daily calorie intake.. · These factors also include lower daily fiber intake, maternal age, prepregnancy BMI, and waist circumference.. · The psychosocial, behavioral, and medical factors associated with GDM did not differ based on race/ethnicity..

Association between gestational weight gain and perinatal outcomes among women with gestational diabetes mellitus

Objective

This study identifies the optimal gestational weight gain (GWG) range for women with gestational diabetes mellitus (GDM) in singleton pregnancies and examines the relationship between GWG patterns and perinatal outcomes.

Methods

We included 18,548 pregnant women diagnosed with GDM via a 75g glucose tolerance test at Fujian Maternal and Child Health Hospital from 2011 to 2022. Data on demographics, GWG, delivery details, and maternal and infant outcomes were collected. Subjects were divided into training and validation sets (7:3 ratio) and classified by pre-pregnancy BMI: underweight, normal weight, overweight, and obese. Logistic regression in the training set was conducted to determine optimal GWG for each group, and examined the relationship between adverse outcomes and the Institute of Medicine(IOM), Chinese nutrition society(CNS), and study-derived (AOR) standards in the validation set.

Results

Among participants, 17.0% pregnant women gained insufficient GWG, 49.2% gained appropriate GWG, and 33.9% with excessive GWG. The optimal GWG for underweight, normal weight, overweight, and women with obesity were 12-14 kg, 8-14 kg, 6-10 kg, and 2-4 kg, respectively. Insufficient GWG in IOM and AOR standard increased composite adverse outcomes among underweight women. Normal weight: Insufficient GWG per CNS and AOR increased composite adverse outcomes; excessive GWG per all standards increased adverse outcomes. Insufficient GWG per all standards reduced the risk of small-for-gestational-age (SGA) infants, while excessive GWG increased the risk of large-for-gestational-age (LGA) infants, gestational hypertension, and cesarean section. Overweight: Excessive GWG per CNS and AOR increased composite adverse outcomes; excessive GWG per all standards increased the risk of cesarean delivery. Obese: Insufficient GWG per IOM and CNS increased composite adverse outcomes.

Conclusion

GWG significantly influences adverse pregnancy outcomes. Compared to IOM guidelines, CNS recommendations and study-derived GWG ranges are more suitable for Chinese women with GDM in singleton pregnancies.

Reevaluating optimal weight changes across the stages of pregnancy

BACKGROUND

While the National Academy of Medicine, formerly known as the Institute of Medicine, recommends the optimum weight change in the second and third trimesters combined, the ideal weight change range per week according to trimesters remains unexplored.

OBJECTIVE

To determine the optimal rates of weight change per week that are associated with decreased adverse pregnancy outcomes for each trimester stratified by prepregnancy body mass index categories.

STUDY DESIGN

This was a secondary analysis of a prospective cohort study using data from the Nulliparous Pregnancy Outcomes Study: Monitoring Mothers-to-Be (2010-2014). Our exposure was the weight change per week, defined as weight change (kg) divided by gestational weeks interval. We examined weight change per week for each trimester: weight change in early pregnancy (early first trimester to second trimester); second trimester (second trimester to third trimester); and third trimester (third trimester to delivery). Our primary outcome was a composite of adverse pregnancy outcomes including hypertensive disorders of pregnancy, preterm birth, spontaneous preterm birth, small-for-gestational-age birth, and stillbirth. To explore potential nonlinear associations between pregnancy weight change and adverse pregnancy outcomes, we applied restricted cubic spline functions with 5 knots. We calculated adjusted relative risks with 95% confidence intervals using generalized linear models with Poisson distribution and robust error variance, controlling for confounders. We estimated adjusted relative risks of adverse pregnancy outcomes for each weight change per week and identified the optimal weight change. The optimal weight change was compared with the National Academy of Medicine-recommended weight change in pregnancy.

RESULTS

Of the 8121 patients included, 4373 (53.8%) had a normal or underweight body mass index, 2002 (24.7%) had an overweight body mass index, and 1746 (21.5%) had an obese body mass index. The weight changes per week associated with the lowest adverse risks for individuals with normal/underweight, overweight, and obese body mass index were 0.7 kg/wk, 0.7 kg/wk, and 0.6 kg/wk, respectively, for the first trimester, 0.7 kg/wk, 0.5 kg/wk, and 0.5 kg/wk, respectively, for the second trimester, and 0.5 kg/wk, 0.4 kg/wk, and 0.4 kg/wk, respectively, for the third trimester. For normal/underweight, weight gain according to the National Academy of Medicine guidelines in the second trimester compared to our optimal weight gain was associated with an increased risk of adverse pregnancy outcomes and preterm birth. For normal/underweight and overweight individuals in the second trimester, weight gain according to the National Academy of Medicine guidelines, compared to our optimal weight gain, was associated with an increased risk of small for gestational age. Conversely, for individuals with obesity in the third trimester, weight gain according to the National Academy of Medicine guidelines compared to our optimal weight gain was associated with a decreased risk of cesarean delivery.

CONCLUSION

The gestational weight change rates associated with the lowest adverse risks were of higher values than those established by the National Academy of Medicine, which may suggest that the National Academy of Medicine guidelines are too strict.

Investigating the Role of Skin Autofluorescence in Gestational Diabetes Mellitus: A Systematic Review

Gestational diabetes mellitus (GDM) is a pregnancy-specific condition that can cause serious complications for both the mother and the fetus. Preventing these complications requires optimum glycemic control. Skin autofluorescence (SAF) is a non-invasive and innovative method that evaluates the levels of advanced glycation end products, markers of hyperglycemia, that could aid in the optimum management of GDM-complicated pregnancies. This systematic review aims to assess SAF's potential utility in the prediction of short-term and long-term outcomes in GDM. Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) methodology, with the protocol identifier CRD42024559012, we used "(skin autofluorescence OR SAF) AND (gestational diabetes mellitus OR GDM)" as a search criterion on the PubMed, Scopus, and Web of Science databases. After a rigorous selection process, we included five articles, which evaluated SAF values and GDM, SAF and pregnancies complicated by diabetes mellitus, and SAF and macrosomia. GDM diagnosis varies due to the different approaches among the major guidelines, leading to variations in interpretation and diagnostic thresholds. Across studies, this variability contributes to inconsistent SAF values. As a standardized and objective marker, SAF could provide a uniform criterion, improving GDM management. Further research is needed to validate its clinical utility.

A retrospective analysis of placental histopathological findings in gestational diabetes mellitus (GDM)

INTRODUCTION

The placenta plays a pivotal role in supporting fetal growth and disruptions in its development and function can impact fetal outcomes. While placental pathology has been extensively studied in clinical conditions such as pre-eclampsia and fetal growth restriction (FGR), the association between placental abnormalities and gestational diabetes mellitus (GDM) is still unclear. This study aims to explore the placental pathology associated with GDM, shedding light on potential links to adverse perinatal outcomes.

METHODS

A retrospective cohort study was conducted using electronic patient data from the Fetal Medicine and Neonatal Units at University College London Hospital. Placental samples were obtained and analysed at Great Ormond Street Hospital. Maternal demographics, obstetric history and placental histopathology were reviewed. Statistical analyses were performed to identify associations and risk factors.

RESULTS

Of the 2580 pregnancies analysed, 341 were GDM pregnancies, 549 had FGR and 66 had both GDM and FGR. GDM pregnancies required increased rates of obstetric intervention and neonatal care admission. Placental pathology in GDM revealed a higher prevalence of maternal vascular malperfusion (MVM) lesions, whilst GDM-related FGR showed further associations with MVM lesions and adverse perinatal outcomes.

DISCUSSION

Our study highlights MVM lesions as a prominent feature in the placentas of GDM pregnancies, especially when associated with FGR. These lesions are linked to adverse perinatal outcomes, emphasizing the need for enhanced antenatal care in these cases. The study contributes insights into the complex relationship between GDM, placental pathology and adverse fetal outcomes, laying the foundation for future investigations into early interventional strategies.

Management of twin pregnancies: Remaining challenges and unanswered questions

Several professional societies have published guidelines on twin pregnancies over the past few years. These documents provide recommendations on antenatal surveillance and management of twin pregnancies. At the same time, these guidelines identify several key areas where evidence is limited and additional research is needed. In the present review, we summarize available evidence regarding some of these key areas, including the screening and prevention of preterm birth, the definition and management of fetal growth restriction, the diagnosis and management of gestational diabetes, the optimal maternal gestational weight gain, and the mode and timing of delivery. In addition, we describe several online tools related to these areas that can empower individuals with twin pregnancies and assist care providers in counseling these patients.

The Hidden Impact of Gestational Diabetes: Unveiling Offspring Complications and Long-Term Effects

BACKGROUND

Gestational diabetes mellitus (GDM), characterized by gestational hyperglycemia due to insufficient insulin response, poses significant risks to both maternal and offspring health. Fetal exposure to maternal hyperglycemia leads to short-term complications such as macrosomia and neonatal hypoglycemia and long-term risks including obesity, metabolic syndrome, cardiovascular dysfunction, and type 2 diabetes. The Developmental Origins of Health and Disease (DOHaD) theory explains how maternal hyperglycemia alters fetal programming, increasing susceptibility to metabolic disorders later in life.

OBJECTIVE

This review explores the intergenerational impact of GDM, linking maternal hyperglycemia to lifelong metabolic, cardiovascular, and neurodevelopmental risks via epigenetic and microbiome alterations. It integrates the most recent findings, contrasts diagnostic methods, and offers clinical strategies for early intervention and prevention.

METHODS

A comprehensive literature search was conducted in PubMed, Scopus, and ScienceDirect to identify relevant studies published between 1 January 2000 and 31 December 2024. The search included studies focusing on the metabolic and developmental consequences of GDM exposure in offspring, as well as potential mechanisms such as epigenetic alterations and gut microbiota dysbiosis. Studies examining preventive strategies and management approaches were also included.

KEY FINDINGS

Maternal hyperglycemia leads to long-term metabolic changes in offspring, with epigenetic modifications and gut microbiota alterations playing key roles. GDM-exposed children face increased risks of obesity, glucose intolerance, and cardiovascular diseases. Early screening and monitoring are crucial for risk reduction.

PRACTICAL IMPLICATIONS

Understanding the intergenerational effects of GDM has important clinical implications for prenatal and postnatal care. Early detection, lifestyle interventions, and targeted postnatal surveillance are essential for reducing long-term health risks in offspring. These findings emphasize the importance of comprehensive maternal healthcare strategies to improve long-term outcomes for both mothers and their children.

Unveiling Gestational Diabetes: An Overview of Pathophysiology and Management

Gestational diabetes mellitus (GDM) is characterized by an inadequate pancreatic β-cell response to pregnancy-induced insulin resistance, resulting in hyperglycemia. The pathophysiology involves reduced incretin hormone secretion and signaling, specifically decreased glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), impairing insulinotropic effects. Pro-inflammatory cytokines, including tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6), impair insulin receptor substrate-1 (IRS-1) phosphorylation, disrupting insulin-mediated glucose uptake. β-cell dysfunction in GDM is associated with decreased pancreatic duodenal homeobox 1 (PDX1) expression, increased endoplasmic reticulum stress markers (CHOP, GRP78), and mitochondrial dysfunction leading to impaired ATP production and reduced glucose-stimulated insulin secretion. Excessive gestational weight gain exacerbates insulin resistance through hyperleptinemia, which downregulates insulin receptor expression via JAK/STAT signaling. Additionally, hypoadiponectinemia decreases AMP-activated protein kinase (AMPK) activation in skeletal muscle, impairing GLUT4 translocation. Placental hormones such as human placental lactogen (hPL) induce lipolysis, increasing circulating free fatty acids which activate protein kinase C, inhibiting insulin signaling. Placental 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) overactivity elevates cortisol levels, which activate glucocorticoid receptors to further reduce insulin sensitivity. GDM diagnostic thresholds (≥92 mg/dL fasting, ≥153 mg/dL post-load) are lower than type 2 diabetes to prevent fetal hyperinsulinemia and macrosomia. Management strategies focus on lifestyle modifications, including dietary carbohydrate restriction and exercise. Pharmacological interventions, such as insulin or metformin, aim to restore AMPK signaling and reduce hepatic glucose output. Emerging therapies, such as glucagon-like peptide-1 receptor (GLP-1R) agonists, show potential in improving glycemic control and reducing inflammation. A mechanistic understanding of GDM pathophysiology is essential for developing targeted therapeutic strategies to prevent both adverse pregnancy outcomes and the progression to overt diabetes in affected women.

Gestational diabetes in early pregnancy is associated with postpartum glucose intolerance: A perspective from the diabetes and pregnancy outcome for mother and baby study in Japan

AIMS

To compare perinatal outcomes and postpartum glucose tolerance between women diagnosed with gestational diabetes mellitus (GDM) before 20 weeks of gestation (EGDM) and those diagnosed at or after 24 weeks of gestation (LGDM) in a Japanese population.

MATERIALS AND METHODS

Data were obtained from a prospective GDM registry. Multivariate analysis was conducted to examine the association between the timing of GDM diagnosis (EGDM vs LGDM) and perinatal outcomes (preterm birth, small for gestational age, large for gestational age, pregnancy-induced hypertension, and neonatal hypoglycemia), as well as postpartum glucose intolerance.

RESULTS

A total of 1,275 mother-infant pairs were analyzed for perinatal outcomes. Of these, 924 women underwent postpartum testing for glucose intolerance. No significant differences in perinatal outcomes were observed between the EGDM and LGDM groups, except that overweight/obese women with EGDM had 2.5-fold higher rate of preterm birth than those with LGDM. Postpartum glucose intolerance was 1.5 times more likely in the EGDM group than in the LGDM group.

CONCLUSIONS

Women with EGDM had a significantly higher risk of postpartum glucose intolerance than those with LGDM, despite similar perinatal outcomes between the two groups.

The Implications of a "Flat" Oral Glucose Tolerance Test Curve in Pregnancy

OBJECTIVE

 This study aimed to determine whether pregnant women who have "flat" oral glucose tolerance test (OGTT) curves in pregnancy are at increased risk of maternal or neonatal adverse outcomes.

STUDY DESIGN

 We conducted a retrospective cohort study of the perinatal outcomes of pregnant women whose 100-g OGTT curve was "flat," defined by a fasting serum glucose level below 95 mg/dL and the remaining values below 100 mg/dL. We compared their perinatal outcomes to women whose OGTT curve was "normal." The primary outcomes compared were the prevalence of macrosomic and small for gestational age (SGA) neonates. Secondary outcomes included hypertensive disorders of pregnancy (HDP), prelabor anemia, thrombocytopenia, intrauterine fetal demise, placental abruption, indicated induction of labor, meconium-stained amniotic fluid, mode of delivery, postpartum hemorrhage, blood product transfusion, postpartum readmission, neonatal gender, gestational age at delivery, preterm birth, birth weight, low birth weight, umbilical artery pH < 7.1, Apgar score <7 at 5 minutes, neonatal intensive care unit admission, neonatal respiratory and infectious morbidity, and hypoglycemia. Composite adverse maternal and neonatal outcomes were also evaluated.

RESULTS

 There were 1,060 patients in the study group and 10,591 patients in the control group. Patients with a flat OGTT were younger (28.3 vs. 29.8, p < 0.001) and less likely to be over 35 years old (14.1 vs. 23.4%, p < 0.001). They had a reduced risk of delivering a macrosomic neonate (11.4 vs. 15.1%, OR = 0.7 [0.58-0.89], p = 0.001) and having an unplanned cesarean delivery (7.5 vs. 10.2%, OR = 0.8 [0.58-0.96], p = 0.002). There was no difference in the rate of composite adverse maternal (14.0 vs. 15.4%, OR = 0.9 [0.7-1.0], p = 0.1) or neonatal outcome (5.3 vs. 4.5%, OR = 1.2 [0.9-1.5], p = 0.15). Neonates had a slightly lower mean birth weight (3,474 vs. 3,505 g, p = 0.04) but the rate of SGA was similar in the two groups (2.5 vs. 1.8%, OR = 1.3 [0.9-2.0], p = 0.08).

CONCLUSION

 Pregnant women whose OGTT curve is flat have a lower risk of delivering macrosomic neonates and undergoing unplanned cesarean delivery and are not at increased risk of adverse maternal or neonatal outcomes. More research is required to evaluate the relationship between different OGTT curves and the fetal growth rate.

KEY POINTS

· Patients with a "flat" OGTT have a reduced risk of macrosomia.. · Patients with a "flat" OGTT have a reduced risk of cesarean delivery.. · Patients with a "flat" OGTT are not at increased risk of growth restriction..

Efficacy and safety of pharmacological treatments for gestational diabetes: a systematic review comparing metformin with glibenclamide and insulin

AIM

Gestational diabetes, characterized by impaired glucose tolerance occurring or diagnosed during pregnancy, is a significant public health concern. When lifestyle and dietary measures fail (30 % of women), insulin is the standard treatment. Oral antidiabetic agents, such as metformin (Glucophage) and glibenclamide, could provide a promising alternative. The aim here was to evaluate the effectiveness and safety of these treatments in gestational diabetes.

METHODS

This study is based on a systematic literature review. A keyword search for "metformin (Glucophage)," "glibenclamide," "pregnancy," and "gestational diabetes" was conducted in the PubMed and Google Scholar databases from 2013 to 2023.

RESULTS

A total of 45 studies were selected and analyzed. metformin (Glucophage) appears to offer a combination of effectiveness in glycemic control and maternal and neonatal safety. Compared to insulin, it reduces maternal weight gain, lowers maternal hypoglycemia rates, and shows a tendency to reduce gestational hypertension and preeclampsia. Additionally, infants born to mothers on metformin (Glucophage) are less likely to be macrosomic, experience fewer neonatal hypoglycemic episodes, and require fewer admissions to intensive care units. On the other hand, glibenclamide seems effective in glycemic control but is associated with higher rates of macrosomia and neonatal hypoglycemia.

CONCLUSION

Metformin (Glucophage) appears to be a promising alternative to insulin for treating gestational diabetes, while uncertainties remain regarding the safety of glibenclamide.

Beyond one size fits all: Probing patient choices in gestational diabetes management, from screening to postpartum

During antenatal care, gestational diabetes mellitus (GDM) screening is crucial for early diagnosis and treatment to ameliorate clinical outcomes and limit health care expenses. Dietary management and physical activity are central to GDM treatment, however, adherence is often influenced by personal preferences, socioeconomic barriers, and psychological stress. Pharmacologically, insulin and oral hypoglycemic medications, are the main GDM treatment that can be subject to patients' resistance due to fears of needles and side effects. Metformin is increasingly preferred for its ease of administration and lower cost. In the postpartum stage, regular screening for type 2 diabetes mellitus (T2DM) should always be considered despite the possible limitations that could arise, including communication gaps, lack of long-term focus, and personal barriers. Overall, women with GDM prefer personalized, flexible management plans that consider their lifestyle, support from health care professionals (HCPs), and family involvement. Addressing psychological and socioeconomic barriers through education, counseling, and support networks is crucial for improving adherence and health outcomes. Enhancing patient-centered care and shared decision-making can empower women with GDM to manage their condition effectively and maintain lifestyle changes postpartum. Therefore, this review aimed to assess pregnant women's preferences in GDM management, focusing on screening, dietary recommendations, physical activity, and treatment. Additionally, this review examined GDM care in terms of these patients' quality of life and postpartum experiences.

Stopping the Intergenerational Risk of Diabetes-From Mechanisms to Interventions: A Report on Research Supported by Pathway to Stop Diabetes

Embedded in the developmental origins of health and disease (DOHaD) hypothesis, maternal hyperglycemia in utero, from preexisting diabetes or gestational diabetes mellitus, predisposes the offspring to excess adiposity and heightened risk of prediabetes and type 2 diabetes development. This transmission creates a vicious cycle increasing the presence of diabetes from one generation to another, leading to the question: How can we interrupt this vicious cycle? In this article, we present the current state of knowledge on the intergenerational transmission of diabetes from epidemiological life course studies. Then, we discuss the potential mechanisms implicated in the intergenerational transmission of diabetes with a focus on epigenetics. We present novel findings stemming from epigenome-wide association studies of offspring DNA methylation in blood and placental tissues, which shed light on potential molecular mechanisms implicated in the mother-offspring transmission of diabetes. Lastly, with a perspective on how to break the cycle, we consider interventions to prevent offspring obesity and diabetes development before puberty, as a critical period of the intergenerational cycle. This article is part of a series of perspectives that report on research funded by the American Diabetes Association Pathway to Stop Diabetes program.

Associations of maternal age with outcomes in very low birth weight singleton infants: a retrospective study

Background

With advances in perinatal medicine, there has been a rise in the preterm birth rate, especially the rate of very low birth weight (VLBW) and extremely low birth weight infants. Studies have shown that maternal age during pregnancy and at the time of delivery is associated with pregnancy complications and poor neonatal outcomes. Little is known about the effect of maternal age on the outcome of very low birth weight infants.

Objectives

To investigate the effects of maternal age on the adverse outcomes of singleton very low birth weight neonates.

Methods

We used data of VLBW infants from the neonatal database of our hospital. Maternal age was categorized as 20-24, 25-34 (reference group), 35-39 and ≥40 years. Statistical analyses included univariate and multivariate logistic regression analysis.

Results

The study ultimately included 603 singleton, very low birth weight infants. After adjustment, neonatal outcomes in the group of older mothers were similar to those of the reference group for bronchopulmonary dysplasia, necrotizing enterocolitis, respiratory distress syndrome, severe asphyxia, retinopathy of prematurity and intraventricular hemorrhage grades 3-4. In the 20-24 year age group higher odds were present for sepsis [Odds ratio (OR) = 6.021; 95% confidence interval (CI), 1.741-20.818, p < 0.05] and for mortality (OR = 7.784; 95% CI, 2.198-27.568, p < 0.05). Higher odds for asphyxia (OR = 1.891; 95% CI, 1.238-2.890, p < 0.05) and death (OR = 2.101, 95% CI, 1.004-4.395, p < 0.05) were observed in infants of mothers in the 35-39 year age group. The incidence of sepsis was significantly higher in the age group of ≥40 years (OR = 2.873; 95% CI, 1.186-6.958, p < 0.05).

Conclusions

In singleton very low birth weight neonates, neonatal outcomes were associated with maternal age, and adverse outcomes were more pronounced in infants of advanced maternal age (AMA) mothers.

Universal screening for hyperglycemia in early pregnancy and the risk of adverse pregnancy outcomes

INTRODUCTION

This study aimed to evaluate the screening outcomes in women with hyperglycemia in early pregnancy (fasting plasma glucose [FPG] 5.1-6.9 mmol/L and/or HbA1c 39-46 mmol/mol before 20 weeks of gestation).

METHODS

This multicenter retrospective cohort study was conducted in China between 2016 and 2022. In our setting, all women without pregestational diabetes performed both FPG and HbA1c screening at the first prenatal visit. Logistic regression models adjusted for confounders were performed to assess the associations of hyperglycemia in early pregnancy with adverse pregnancy outcomes. Subgroup analyses were explored according to the subsequent diagnosis of gestational diabetes (GDM, with or without).

RESULTS

Of the 42,999 women in the analysis, 2515 (5.8%) women had hyperglycemia in early pregnancy. Compared with women with normal FPG and HbA1c levels, women with FPG 5.1-6.9 mmol/L and/or HbA1c 39-46 mmol/mol had a 3-fold increased risk of GDM (aOR 3.85; 95% CI 3.52-4.20), and 1-fold higher risk of hypertensive disorders of pregnancy (1.42; 1.20-1.67), shoulder dystocia (1.30; 1.11-1.52), preterm birth (1.30; 1.11-1.52), large-for-gestational-age (1.26; 1.12-1.43), and macrosomia (1.43; 1.19-1.73). Women with hyperglycemia in early pregnancy complicated by GDM were associated with a 50%, 84%, 48% and 24% increase in the odds of developing hypertensive disorders of pregnancy (1.50; 1.21-1.84), preterm premature rupture of membranes (1.84; 1.09-3.10), preterm birth (1.48; 1.22-1.81) and large-for-gestational-age (1.24; 1.05-1.45), respectively, compared with those without hyperglycemia.

CONCLUSIONS

Pregnant women with hyperglycemia in early pregnancy have an increased risk of adverse pregnancy outcomes, and women with these conditions complicated by GDM are at higher risk than those without. Further research is needed to explore whether the incidence of GDM can be reduced by early intervention and therefore prevent the relevant adverse pregnancy outcomes.

The Role of Placental MFF-Mediated Mitochondrial Fission in Gestational Diabetes Mellitus

Introduction

Gestational diabetes mellitus (GDM) refers to hyperglycemia first recognized during pregnancy, characterized by decreased insulin sensitivity and impaired glucose metabolism. Dynamic fusion and fission processes within mitochondria play critical roles in maintaining glucose metabolism homeostasis. Given the fundamental role of mitochondrial fission factor (MFF) in mitochondrial fission, the intention of this study was to investigate mitochondrial dynamics in the placentae of GDM patients and explore the role of MFF in the etiopathogenesis and progression of GDM through the modulation of glucose metabolism and insulin resistance.

Methods

40 Placental tissues were obtained from pregnant women undergoing cesarean section with GDM (n=20) and those with normoglycemia (n=20). To mimic the intrauterine high glucose environment, immortalized human-derived first-trimester extravillous trophoblast cells HTR8/SVneo were used and treated in a high glucose environment. Immunofluorescence was utilized to analyze MFF expression in placental tissues and mitochondrial length in HTR8/SVneo cells. The expression levels of glucose transporters (GLUTs) and other pivotal proteins involved in mitochondrial dynamics and the insulin signaling pathway, were assessed by Western blotting. Additionally, cellular glucose uptake capacity was determined using a glucose assay kit.

Results

MFF expression was greater in the GDM group than in the normoglycemic group. In a high-glucose environment, the expression of fusion-related proteins OPA1, MFN1 and MFN2 decreased while the expression of DRP1 and MFF increased, indicating that the mitochondrial dynamics of trophoblast cells shift toward fission. Elevated mitochondrial fission hinders the insulin signaling pathway, resulting in a reduction in glucose uptake by HTR8/SVneo cells and a concurrent decrease in GLUT4 expression.

Discussion

Our study demonstrates that MFF-mediated mitochondrial fission inhibits insulin sensitivity and upregulates glucose transport in GDM, which is related to offspring exposure to a hyperglycemic intrauterine environment. These results provide a novel therapeutic target for addressing GDM that may mitigate unfavorable pregnancy outcomes.

Comprehensive Assessment of Biventricular and Biatrial Myocardial Strain Parameters at 4 Years Postpartum in a Cohort of Women with Previous Gestational Diabetes Mellitus

Background/Objectives: No previous study has provided a comprehensive evaluation of all biventricular and biatrial myocardial strain parameters in women with previous gestational diabetes mellitus (pGDM). Accordingly, we aimed at investigating the structural and myocardial deformation properties of all cardiac chambers in a cohort of pGDM women at 4 years postpartum. Methods: A consecutive cohort of pGDM women was compared to a control group of healthy women with previous uncomplicated pregnancy, matched by age, ethnicity and gestational week, at 4 years postpartum. Both groups of women underwent transthoracic echocardiography (TTE) implemented with speckle-tracking echocardiography (STE) and subsequent carotid ultrasonography. The primary endpoint was subclinical myocardial dysfunction, defined as left-ventricular (LV) global longitudinal strain (GLS) < 20%, whereas the secondary endpoint was early carotid atherosclerosis, defined as common carotid artery (CCA) intima-media thickness (IMT) ≥ 0.7 mm. Results: A total of 32 pGDM women (39.1 ± 6.5 yrs) and 30 matched healthy controls (40.8 ± 5.0 yrs) were analyzed. Despite normal and similar systolic function on conventional TTE, all biventricular and biatrial strain parameters were significantly lower in pGDM women than controls. Mean follow-up period was 4.0 ± 1.9 yrs. During follow-up, 62.5% of pGDM women developed subclinical myocardial dysfunction, and 78.1% of them were diagnosed with early carotid atherosclerosis. Third-trimester BMI (OR 1.88, 95% CI 1.19-2.98) and third-trimester glycosylated hemoglobin (HbA1C) (OR 2.34, 95% CI 1.08-5.04) were independently associated with the primary endpoint. Third-trimester BMI and HbA1C also independently predicted the secondary endpoint. Third-trimester BMI > 27 kg/m2 and HbA1C > 33 mmol/mol showed the best sensitivity and specificity for predicting both endpoints. Conclusions: Women with a previous history of GDM complicated by overweight/obesity and uncontrolled diabetes have a significantly increased risk of subclinical myocardial dysfunction and early carotid atherosclerosis at 4 years postpartum.

Association between isolated abnormal 1-hour glucose challenge test and adverse pregnancy outcomes: a retrospective review from an urban tertiary care center in the United States

BACKGROUND

The objective of this study was to investigate whether an isolated abnormal 1-hour glucose challenge test (GCT) among patients without gestational diabetes (GDM) is associated with adverse outcomes.

METHODS

This is a retrospective cohort study of patients who underwent GDM screening at ≥ 24 weeks' gestation with a 1-hour GCT and delivered a singleton fetus at > 35 weeks' gestation at an urban tertiary hospital from 1/2013 to 10/2021. Data were extracted from an electronic medical record data warehouse using standardized billing/diagnosis codes. Individuals were categorized into 3 groups: normal screening (1-hour GCT value < 140 mg/dL), intermediate screening (1-hour GCT value ≥ 140 and < 200 but normal 3-hour glucose tolerance test (GTT)), and GDM (1-hour GCT ≥ 200 mg/dL or abnormal 3-hour GTT). The primary composite perinatal morbidity outcome included any of the following: large for gestational age (LGA) birthweight, birth injury, hypoglycemia with neonatal intensive care unit (NICU) admission, respiratory distress syndrome, transient tachypnea of the newborn, apnea, NICU admission, or perinatal death. Multiple secondary outcomes were also evaluated. Bivariable analyses and multivariable logistic regression modeling were performed.

RESULTS

Of 37,277 eligible patients, 29,698 (79.7%) had normal screening results, 5092 (13.7%) had intermediate screening results, and 2487 (6.6%) were diagnosed with GDM. There were significant differences in baseline characteristics between the three groups, including age, parity, race and ethnicity, payer-type, obesity, and pre-pregnancy metformin use. Compared to normal screening, intermediate screening was associated with an increased risk for the composite perinatal morbidity outcome (OR 1.23, 95% CI 1.15-1.32), cesarean (OR 1.37, 95% CI 1.28-1.46), and hypertensive disorders of pregnancy (OR 1.30, 95% CI 1.20-1.40). Associations for these outcomes were further pronounced in those with GDM compared to normal screening (OR 1.86, 95% CI 1.70-2.03; OR 1.69, 95% CI 1.56-1.84; and OR 1.57, 95% CI 1.42-1.74, respectively). After adjusting for potential confounders, increased risks for the composite perinatal morbidity outcome persisted for those with intermediate screening (aOR 1.18, 95% CI 1.10-1.26).

CONCLUSIONS

In addition to patients with GDM, individuals an isolated abnormal 1-hour GCT without GDM were also at increased risks for adverse pregnancy outcomes. Further investigation is needed to understand if patients with mild dysregulation may still benefit from other interventions.

Impact of Vitamin D Deficiency on Gestational Diabetes and Pregnancy Outcomes Across Diverse Ethnic Groups: A Retrospective Cohort Study

Background: Vitamin D deficiency is linked to adverse pregnancy outcomes like gestational diabetes mellitus (GDM), but its effects across ethnic groups are unclear. This study examines the relationship among vitamin D levels, glucose tolerance, GDM prevalence, and neonatal outcomes in a multi-ethnic cohort of pregnant women. Methods: We conducted a retrospective analysis of 252 pregnant women from antenatal clinics between 2018 and 2022. Participants were divided into four groups based on serum vitamin D levels: severely deficient (<25 nmol/L), deficient (25-50 nmol/L), insufficient (51-75 nmol/L), and sufficient (>75 nmol/L). The analysis included multivariate linear regression models adjusted for age, ethnicity, BMI, gestational diabetes status, and seasonality. An area under the receiver operating characteristic (AUROC) analysis identified the vitamin D threshold linked to an increased GDM risk. Results: Women classified as severely deficient had higher fasting glucose levels (5.73 ± 1.24 mmol/L) than those in other groups (p = 0.003, adjusted). The AUROC analysis identified a vitamin D threshold of 45 nmol/L associated with an elevated GDM risk (AUROC = 0.78, CI: 0.70-0.85). South Asian women had lower vitamin D levels (41.17 ± 18.03 nmol/L vs. 45.15 ± 16.75 nmol/L) and higher glucose tolerance test (GTT) levels than Caucasian women, despite having lower BMIs. Moreover, vitamin D levels positively correlated with neonatal birth weight (p = 0.02). Conclusions: There is a strong link between vitamin D deficiency and increased GDM risk, especially among South Asian women. These findings underscore the need for targeted interventions to improve vitamin D levels in high-risk ethnic groups.